Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ

被引:1
|
作者
Sawyer, C
Sturge, J
Bennett, DC
O'Hare, MJ
Allen, WE
Bain, J
Jones, GE
Vanhaesebroeck, B [1 ]
机构
[1] Univ Coll & Royal Free Med Sch Branch, Ludwig Inst Canc Res, Cell Signaling Grp, London W1W 7BS, England
[2] Kings Coll London, Randall Ctr Mol Mech Cell Funct, London SE1 1UL, England
[3] St George Hosp, Sch Med, Dept Anal & Dev Biol, London SW17 0RE, England
[4] Royal Free & Univ London Coll, Ludwig Inst Canc Res, Sch Med, Breast Canc Lab,Dept Surg, London W1W 7EJ, England
[5] Queens Univ Belfast, Inst Clin Sci, Dept Clin Biochem, Belfast BT12 6BJ, Antrim, North Ireland
[6] Univ Dundee, Sch Life Sci, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland
[7] UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Class IA phosphoinositide 3'-kinases (PI3Ks) regulate many cellular processes downstream of tyrosine kinases and Ras. Despite a clear implication of PI3K in cancer, little is known about the distribution of the different PI3K isoforms in malignant cells. We screened a large panel of tissues and cell lines for expression of class IA PI3Ks, and document a ubiquitous expression of the p110alpha and p110beta isoforms but a variable and more restricted tissue distribution of the p110delta isoform. Originally found in WBCs, p110delta was also detected in some nonhematopoietic cell types especially those of breast or melanocytic origin, both in the untransformed and transformed state. Isoform-specific neutralization of PI3K isoforms in breast cancer cell lines.(by PI3K antibody microinjection or a p110delta-selective pharmacological inhibitor) demonstrated that p110delta is the most important class IA PI3K in the regulation of epidermal growth factor-driven motility in vitro, controlling the directionality and, to a lesser extent, the speed of migration. In contrast, p110beta was required for the direction but not the speed of migration, whereas p110alpha did not impact on either of these parameters. These results show a nonredundant function of PI3K isoforms downstream of the epidermal growth factor receptor and indicate that the presence of p110delta may confer breast cancer cells with selective migratory capacities. The potential clinical implications of p110delta expression in non-WBC-derived tumors are discussed.
引用
收藏
页码:1667 / 1675
页数:9
相关论文
共 50 条
  • [41] Gαq binds to p110α/p85α phosphoinositide 3-kinase and displaces Ras
    Ballou, LM
    Chattopadhyay, M
    Li, Y
    Scarlata, S
    Lin, RZ
    BIOCHEMICAL JOURNAL, 2006, 394 : 557 - 562
  • [42] Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110γ
    Kurig, Barbara
    Shymanets, Aliaksei
    Bohnacker, Thomas
    Prajwal
    Brock, Carsten
    Ahmadian, Mohammad Reza
    Schaefer, Michael
    Gohla, Antje
    Harteneck, Christian
    Wymann, Matthias P.
    Jeanclos, Elisabeth
    Nuernberg, Bernd
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (48) : 20312 - 20317
  • [43] Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ
    Brock, C
    Schaefer, M
    Reusch, HP
    Czupalla, C
    Michalke, M
    Spicher, K
    Schultz, G
    Nürnberg, B
    JOURNAL OF CELL BIOLOGY, 2003, 160 (01): : 89 - 99
  • [44] Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy
    McMullen, Julie R.
    Amirahmadi, Fatemeh
    Woodcock, Elizabeth A.
    Schinke-Braun, Martina
    Bouwman, Russell D.
    Hewitt, Kimberly A.
    Mollica, Janelle P.
    Zhang, Li
    Zhang, Yunyu
    Shioi, Tetsuo
    Buerger, Antje
    Izumo, Seigo
    Jay, Patrick Y.
    Jennings, Garry L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (02) : 612 - 617
  • [45] PHOSPHOINOSITIDE 3-KINASE P110{GAMMA} IS REQUIRED FOR BACTERIAL CLEARANCE AND THE RESOLUTION OF EXPERIMENTAL COLITIS
    Prescott, D. C.
    Atkinson, B.
    McKay, D. M.
    Waterhouse, C.
    INFLAMMATION RESEARCH, 2011, 60 : 34 - 34
  • [46] Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations
    Cornillet-Lefebvre, P
    Cuccuini, W
    Bardet, V
    Tamburini, J
    Gillot, L
    Ifrah, N
    Nguyen, P
    Dreyfus, F
    Mayeux, P
    Lacombe, C
    Bouscary, D
    LEUKEMIA, 2006, 20 (02) : 374 - 376
  • [47] Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors
    Yiping Li
    Yawen Wang
    Fuqiang Zhang
    Journal of Molecular Modeling, 2010, 16 : 1449 - 1460
  • [48] The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells
    Okkenhaug, Klaus
    Patton, Daniel T.
    Bilancio, Antonio
    Garcon, Fabien
    Rowan, Wendy C.
    Vanhaesebroeck, Bart
    JOURNAL OF IMMUNOLOGY, 2006, 177 (08): : 5122 - 5128
  • [49] Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells
    Boller, Danielle
    Schramm, Alexander
    Doepfner, Kathrin T.
    Shalaby, Tarek
    von Bueren, Andre O.
    Eggert, Angelika
    Grotzer, Michael A.
    Arcaro, Alexandre
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1172 - 1181
  • [50] The p110δ subunit of phosphoinositide 3-kinase is required for the lipopolysaccharide response of mouse B cells
    Hebeis, BJ
    Vigorito, E
    Turner, M
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 789 - 791